$489 Million is the total value of Omega Fund Management, LLC's 22 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 9.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NUVB | Nuvation Bio | $120,756,000 | -38.1% | 22,957,340 | 0.0% | 24.71% | -10.4% | |
| REPL | Sell | Replimune Group | $79,354,000 | -38.5% | 4,673,380 | -1.9% | 16.24% | -11.0% |
| Imago Biosciences | $58,171,000 | -18.7% | 3,018,737 | 0.0% | 11.90% | +17.6% | ||
| MORF | Morphic Holding | $48,181,000 | -15.3% | 1,200,014 | 0.0% | 9.86% | +22.7% | |
| KRON | Kronos Bio | $27,606,000 | -46.8% | 3,818,283 | 0.0% | 5.65% | -23.0% | |
| GOSS | Gossamer Bio | $27,471,000 | -23.3% | 3,164,835 | 0.0% | 5.62% | +11.1% | |
| IMUX | Immunic Inc | $20,206,000 | +18.1% | 1,788,160 | 0.0% | 4.14% | +70.9% | |
| ALPN | Alpine Immune Sciences | $18,205,000 | -35.2% | 2,029,580 | 0.0% | 3.73% | -6.2% | |
| New | Cincor | $16,947,000 | – | 966,176 | +100.0% | 3.47% | – | |
| IKNA | Ikena Oncology | $13,720,000 | -51.4% | 2,249,123 | 0.0% | 2.81% | -29.6% | |
| ARQT | Arcutis Biothereapeutics | $12,015,000 | -7.1% | 623,836 | 0.0% | 2.46% | +34.4% | |
| Theseus Pharmaceuticals | $8,203,000 | -9.1% | 711,479 | 0.0% | 1.68% | +31.6% | ||
| SANA | Sana Biotechnology, Inc. | $6,969,000 | -46.6% | 843,750 | 0.0% | 1.43% | -22.8% | |
| PRTK | Paratek Pharmaceuticals | $5,855,000 | -33.8% | 1,971,241 | 0.0% | 1.20% | -4.2% | |
| OMEG | Omega Alpha SPAC | $4,920,000 | +0.5% | 501,000 | 0.0% | 1.01% | +45.5% | |
| SPRB | Spruce Biosciences | $4,344,000 | -54.9% | 2,161,022 | 0.0% | 0.89% | -34.8% | |
| CMPI | Checkmate Pharmaceuticals | $4,259,000 | +11.1% | 1,335,050 | 0.0% | 0.87% | +60.9% | |
| Icosavax | $3,002,000 | -69.2% | 426,395 | 0.0% | 0.61% | -55.5% | ||
| SYRS | Syros Pharmaceuticals | $2,990,000 | -63.5% | 2,512,705 | 0.0% | 0.61% | -47.2% | |
| EPIX | ESSA Pharma | $2,028,000 | -56.5% | 328,196 | 0.0% | 0.42% | -37.0% | |
| JNCE | Jounce Therapeutics | $1,871,000 | -18.7% | 275,513 | 0.0% | 0.38% | +17.8% | |
| IMCR | Immunocore Holdings | $1,541,000 | -12.7% | 51,535 | 0.0% | 0.32% | +26.0% | |
| Exit | Adagio Therapeutics | $0 | – | -632,855 | -100.0% | -0.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.